Introduction

Worldwide, 90,000 [1] allogeneic HSCTs were performed between 2001 and 2011, with 4369 [2] of these procedures occurring in Australia. With improvements in donor selection, conditioning therapies, and supportive care, 35–80% of HSCT recipients can now be expected to become long-term survivors and be cured of their underlying disease [3]. While HSCT provides a clear benefit for many patients with malignant and nonmalignant disease, it is also associated with significant morbidity and mortality [4].
In recent years, there has been growing literature on the long-term (or late) psychosocial and medical complications experienced by HSCT survivors. The impact of these is profound with HSCT survivors experiencing a 30% lower life expectancy than a matched population cohort [4]. While many survivors rate their quality of life highly at 2 years posttransplant, many HSCT recipients experience considerable difficulty coping with the short-, medium-, and long-term physical and psychological sequelae of HSCT and with the uncertainties of their prognosis. Given the extent and impact of late complications of HSCT, ongoing long-term follow-up and multidisciplinary care of HSCT recipients is essential [5].

In addition to prescribed conventional medicines, many HSCT survivors also use complementary and alternative medical therapies (CAM). However, the prevalence and extent of the usage of CAMs in this patient group remains unclear. A review published in 1998 found the prevalence of CAM use among cancer patients ranges from 7% to 64% of patients sampled in 26 studies conducted worldwide [6]. This is consistent with CAM use in the general population, estimated at 40% in Australia, Canada, Europe, New Zealand, and the United States [7].

Studies in the United States have reported that the most common complementary practices and products used by individuals with cancer are vitamin/mineral supplements, prayer for self, intercessory prayer, chiropractic/osteopathic manipulation, and herbal therapies [8]. To date, no studies have reported CAM usage by HSCT patients.

Despite the lack of literature on the epidemiology of CAM use in HSCT patients, there have been a number of small trials, including randomized controlled studies showing a potential benefit for some CAM therapies such as mind and body interventions, although the majority of CAM treatments show inconclusive mixed results [9]. The authors of a recent literature review of these known studies of CAMs in HSCT proposed that a current barrier to the use and research in CAM therapy is the recognition and acceptance of CAM use in this population and that epidemiologic estimates were required [9]. The aim of this study was to describe the frequency and types of CAM use by HSCT survivors, with the intention of enhancing recognition of CAM use.

**Methods**

**Patients and procedures**

Study participants were eligible if they were ≥18 years of age and had undergone an allogeneic HSCT between 1st January 2000 and 31st December 2012 in New South Wales (NSW) (NSW is Australia’s most populous state – with a population of ~7.5 million [10]), and could read and write English. Potential participants were identified from the transplant databases of all allogeneic transplant centers in NSW, with names and phone numbers provided to the research team. Consenting participants were given the option to self-complete the questionnaire or to complete it via a phone interview with one of the researchers. A second round of telephone calls was made to consenting participants who had not returned the survey within a month. The study protocol was approved by the Northern Sydney Coast Human Research Ethics Committee (NSLHD Reference: 1207–217M).

**Instruments**

The Sydney Post HSCT Study survey (SPBS) was developed by the research team. Item construction was informed by a review of the literature and discussions with patients attending HSCT long-term follow-up clinics. It consisted of 402 questions, including questions relating to the use of CAMs, specifically: Nutrition and Dietary approaches, Herbal supplements, Vitamin therapies, Mind–Body therapies (e.g., Meditation), Manipulative and Body therapies (e.g., Acupuncture), Traditional medicine (e.g., Traditional Chinese Medicine), Energy medicine (e.g., Reiki), and Homeopathy. Other relevant domains included demographic data, medical complications, specialist referrals, tests and assessments, medications and therapies, infections, vaccinations, cancer screening, close personal contacts, lifestyle, occupation, and relationship status following stem cell transplantation. The questionnaire used tick box response, short answer questions, and 5-step Likert scales measuring attitudes and other factors, and takes approximately 1 h to complete. The questionnaire was piloted in clinic and phone interviews to assess face and content validity and to check for comprehension of the survey questions.

An additional one page HSCT clinical data form (The Sydney Post HSCT Clinical Data Form) was used to collect information from the transplant database including date of transplant, date of diagnosis, stage at transplant, transplant conditioning, Graft-versus-Host Disease (GvHD) prophylaxis, stem cell source, and donor type.

**Measures**

Participants were classified as CAM users if they used at least one therapy in any of the CAM categories. CAM use was correlated with demographics, medical complications, posttransplant medical therapies, treatments and clinical variables, relationship status, and social determinants including income and occupational status. The relationship of CAM use was further explored against a range of survey instruments that measured quality of life...
(Functional Assessment of Cancer Therapy – Bone Marrow Transplant (FACT-BMT Version 4), anxiety, stress, and depression (The DASS 21), chronic GVHD (The Chronic GVHD Activity Assessment – Patient Self Report (Form B) and The Lee Chronic GVHD Symptom Scale), and an assessment of life change in response to traumatic events (The Post Traumatic Growth Inventory score).

Statistical considerations

Categorical responses were summarized using frequencies and percentages. Parametric continuous variables were summarized using means and standard deviations, and nonparametric variables using medians and interquartile ranges. The Pearson’s X² test or Fishers Exact tests were used for comparative analysis of dichotomous categorical variables. Two sample comparisons of means and medians were determined using the independent t test and Wilcoxon Rank Sum tests, respectively; greater than two sample comparisons of means and medians were determined using one-way analysis of Variance (ANOVA) and Kruskal–Wallis tests, respectively. A two-tailed P < 0.05 was used as the level of statistical significance.

Results

Study subjects

A total of 1475 Allogeneic HSCT were performed in the study period. Of the 669 recipients known to be alive at study sampling, 583 were contactable and were sent study packs. A total of 432 (66% of total eligible, 76% of those contacted) returned the completed survey. Three percent declined participation.

Transplantation details

Median survival time post-HSCT was 5 years (range: 1 year 4 months–22 years). The main indication for transplantation was acute leukemia (AML/ALL) in 226 (52.3%). Remission status was reported in 406 HSCT, of which 271 (66.8%) were CR1 or CR2. Donor type was reported in 432 transplant procedures of which the majority were siblings (57.1%) and matched unrelated donors (35.8%). Peripheral blood stem cells were used in 381 (88.1%) of transplants. Myeloablative conditioning regimens were used in 216 (50.0%) and of these 103 (47.7%) employed total body irradiation (TBI). T-cell depleting therapy was reported in 122 (28.2%). Antithymocyte globulin (ATG) accounted for 92.6% of T-depleting modalities, with Alemtuzumab accounting for 3.3%.

Usage of complementary and alternative medicine therapies

A total of 239 (54.2%) of HSCT survivors used at least one form of CAM, including dietary modification (13.4%), vitamin therapy (including minerals and oils) (29.3%), spiritual and mind–body therapy (17.2%), herbal supplements (13.2%), manipulative and body-based therapies (25.4%), Chinese medicine (3.4%), reiki (3%), and homeopathy (3%) (Table 1). One hundred and seventeen (27.2%) patients used more than one form of CAM, ranging up to seven forms of CAM (Table 2).

Characteristics of CAM users are shown in Table 3. There was no age difference between CAM users and nonusers. Women (P = 0.019), people living in a major city (P = 0.017), those with a university education (P = 0.001), and those with bone disease (P = 0.029) were significantly more likely to use at least one CAM. When comparing pretransplant diagnosis, type of conditioning or time from transplant, cGvHD, diabetes, cardiovascular risk, thyroid problems, anxiety, and depression, no difference in CAM use was seen.

Additionally, patients taking antibacterial, antiviral, or antifungal treatment were significantly less likely to use CAMs (P = 0.041), whereas patients taking other prescription drugs, including immunosuppressant, cardiovascular, hormone replacement, or psychotropic medications, were no more or less likely to use CAMs. Patients who routinely saw a Psychologist (P = 0.024) or Physiotherapist (P = 0.010) were more likely to use CAMs, as were those who did regular exercise (P = 0.049). There was no

Table 1. Total complementary and alternative medical therapies (CAM) usage.

| Overall CAM users | 54.2% (239) |
|-------------------|-------------|
| Dietary modification | 13.6% (59) |
| Vitamin therapy (ex Calcium/Vit D) | 27.3% (109) |
| Mind–body therapy (inc spiritual) | 17.2% (74) |
| Herbal supplementation | 13.5% (58) |
| Manipulative and body-based therapies | 26.0% (112) |
| Chinese medicine | 3.5% (15) |
| Reiki | 3.0% (13) |
| Homeopathy | 3.0% (13) |

Table 2. Total complementary and alternative medical therapies (CAM) burden.

| Number of CAMs | Nil | At least 1 | 1 | 2 | 3 | 4 | 5 | 6 | 7 |
|----------------|----------------|-------------|---|---|---|---|---|---|---|
| Patients       | 43.8% (193)   | 54.2% (239) | 26.0% (116) | 14.5% (62) | 6.6% (27) | 4.3% (17) | 0.9% (4) | 0.9% (4) | 0.7% (3) |
Table 3. Characteristics of CAM users.

| Variables                              | CAM users (%) | Nonusers (%) | P value | OR (CI) |
|----------------------------------------|---------------|--------------|---------|---------|
| Demographic                            |               |              |         |         |
| Gender                                 | 123/239 (51.5)| 121/193 (62.7)| 0.019   | 0.63 (0.42–0.92) |
| Male (n = 244)                         | 116/239 (48.5)| 72/193 (37.3) |         |         |
| Female (n = 188)                       |               |              |         |         |
| Age (years)                            | 124/239 (51.9)| 97/193 (50.3) | 0.73    | 1.06 (0.73–1.56) |
| <54 (n = 221)                          | 115/239 (48.1)| 96/193 (49.7) |         |         |
| ≥54 (n = 211)                          |               |              |         |         |
| Postcode                               | 180/234 (76.9)| 125/188 (66.5)| 0.017   | 1.68 (1.0–2.5) |
| City – metro (n = 305)                 | 54/234 (23.1) | 63/188 (33.5) |         |         |
| Regional or remote (n = 117)           |               |              |         |         |
| Socioeconomic                          |               |              |         |         |
| Education                               | 98/179 (54.7) | 52/146 (35.6) | 0.001   | 2.18 (1.36–3.42) |
| Some high school (n = 53), completed   | 81/179 (45.3) | 94/146 (64.4) |         |         |
| high school (n = 78), Trade/diploma    |               |              |         |         |
| Some university (n = 24), completed     |               |              |         |         |
| university (n = 126)                   |               |              |         |         |
| University education (n = 150)         | 180/234 (76.9)| 125/188 (66.5)|         |         |
| Other (n = 175)                        | 54/234 (23.1) | 63/188 (33.5) |         |         |
| Posttransplant income                  | 81/230 (35.2) | 72/185 (38.9) | 0.43    | 0.85 (0.57–1.27) |
| Low income (n = 153)                   | 149/230 (64.8)| 113/185 (61.1)|         |         |
| Middle-high income (n = 262)           |               |              |         |         |
| Occupational status                    | 118/220 (53.6)| 93/194 (47.9) | 0.24    | 1.25 (0.85–1.85) |
| Full/Part time (n = 211)               | 102/220 (46.4)| 101/194 (52.1)|         |         |
| Unemployed, Retired or Casual (n = 203) |               |              |         |         |
| Transplant factors                     |               |              |         |         |
| Pretransplant cancer diagnosis         | 122/228 (53.5)| 97/186 (52.2) | 0.78    | 1.05 (0.71–1.55) |
| Acute leukemia (n = 219)               | 106/228 (46.5)| 89/186 (47.8) |         |         |
| Other (n = 195)                        |               |              |         |         |
| Years since transplant                 | N = 239       | N = 193      | 0.053   | –       |
| <2 years (n = 57)                      | 27 (11.3)     | 30 (15.5)    |         |         |
| 2 < 6 years (n = 199)                  | 105 (43.9)    | 94 (48.7)    |         |         |
| 6 < 10 years (n = 115)                 | 64 (26.8)     | 51 (26.4)    |         |         |
| ≥10 years (n = 61)                     | 43 (18)       | 18 (9.3)     |         |         |
| Conditioning                           | 239           | 193          | 0.213   | –       |
| Myeloablative (n = 216)                |               |              |         |         |
| Reduced intensity (n = 225)            | 122 (51)      | 88 (45.6)    |         |         |
| Missing (n = 2)                        | 115 (48.1)    | 105 (54.5)   |         |         |
| Clinical factors                       |               |              |         |         |
| cGvHD                                  | N = 233       | N = 192      | 0.39    | 1.23 (0.82–1.87) |
| Yes (n = 294)                          | 166 (71.2)    | 128 (66.7)   |         |         |
| No (n = 131)                           | 67 (28.8)     | 64 (33.3)    |         |         |
| Diabetes                               | N = 209       | N = 180      | 0.75    | 0.91 (0.51–1.6) |
| Yes (n = 56)                           | 29 (13.9)     | 27 (15)      |         |         |
| No (n = 333)                           | 180 (86.1)    | 153 (85)     |         |         |
| Thyroid                                | N = 205       | N = 176      | 0.40    | 1.50 (0.57–3.9) |
| Yes (n = 19)                           | 12 (5.9)      | 7 (4.0)      |         |         |
| No (n = 362)                           | 193 (94.1)    | 169 (96.0)   |         |         |
| CV Risk                                | N = 219       | N = 186      | 0.49    | 1.14 (0.77–1.70) |
| Yes (n = 175)                          | 98 (44.7)     | 77 (41.4)    |         |         |
| No (n = 230)                           | 121 (55.3)    | 109 (58.6)   |         |         |
| Self-reported anxiety or depression    | N = 215       | N = 185      | 0.142   | 1.38 (0.89–2.15) |
| Yes (n = 1160)                         | 69 (32.1)     | 47 (25.4)    |         |         |
| No (n = 284)                           | 146 (67.9)    | 138 (74.6)   |         |         |
| Bone disease                           | N = 214       | N = 178      | 0.029   | 1.62 (1.04–2.52) |
| Yes (n = 121)                          | 76 (35.5)     | 45 (25.3)    |         |         |
| No (n = 271)                           | 138 (64.5)    | 133 (74.7)   |         |         |

(Continues)
Table 3. Characteristics of CAM users. (Continued)

| Variables                                      | CAM users (%) | Nonusers (%) | P value | OR (CI)   |
|------------------------------------------------|---------------|--------------|---------|-----------|
| **Skin/Mouth cancers**                         |               |              |         |           |
| Yes (n = 94)                                   | 53 (24.7)     | 41 (22.4)    | 0.59    | 1.13 (0.71–1.85) |
| No (n = 304)                                   | 162 (75.3)    | 142 (77.6)   |         |           |
| **Other medication use**                       |               |              |         |           |
| Med group 1 (penicillin, antiviral drug, bactrim, antifungal drug) | N = 239       | N = 193      | 0.041   | 0.66 (0.45–0.98) |
| Yes (n = 176)                                  | 87 (36.4)     | 89 (46.1)    |         |           |
| No (n = 256)                                   | 152 (63.6)    | 104 (53.9)   |         |           |
| Med group 2 (immune drug, prednisolone)       | N = 239       | N = 193      | 0.31    | 0.81 (0.54–1.21) |
| Yes (150)                                      | 78 (32.6)     | 72 (37.3)    |         |           |
| No (282)                                       | 161 (67.4)    | 121 (62.7)   |         |           |
| Med group 3 (any blood pressure drug)         | N = 239       | N = 193      | 0.16    | 0.73 (0.47–1.13) |
| Yes (107)                                      | 53 (22.2)     | 186 (77.8)   |         |           |
| No (325)                                       | 54 (28)       | 139 (72)     |         |           |
| Med group 4 (antidepressant, any sleeping tablet, antianxiety drug) | N = 239       | N = 193      | 0.50    | 1.17 (0.73–1.88) |
| Yes (89)                                       | 52 (21.8)     | 187 (78.2)   |         |           |
| No (343)                                       | 37 (19.2)     | 156 (80.8)   |         |           |
| Calcium                                        | N = 239       | N = 193      | 0.27    | 1.23 (0.84–1.50) |
| Yes (205)                                      | 119 (49.8)    | 86 (44.6)    |         |           |
| No (227)                                       | 120 (50.2)    | 107 (55.4)   |         |           |
| Med group 5 (hormonal replacement)             | N = 239       | N = 193      | 0.116   | 1.55 (0.89–2.73) |
| Yes (62)                                       | 40 (16.7)     | 22 (11.4)    |         |           |
| No (370)                                       | 199 (83.3)    | 171 (88.6)   |         |           |
| **Psychosocial**                               |               |              |         |           |
| Psychiatrist                                   | N = 220       | N = 181      | 0.99    | 0.99 (0.47–2.08) |
| Yes (n = 31)                                   | 17 (7.7)      | 14 (7.7)     |         |           |
| No (n = 370)                                   | 203 (92.3)    | 167 (92.3)   |         |           |
| Psychologist                                   | N = 221       | N = 185      | 0.024   | 1.82 (1.07–3.09) |
| Yes (n = 74)                                   | 49 (22.2)     | 25 (13.5)    |         |           |
| No (n = 332)                                   | 172 (77.8)    | 160 (86.5)   |         |           |
| Social worker                                  | N = 221       | N = 183      | 0.21    | 1.4 (0.79–2.67) |
| Yes (n = 51)                                   | 32 (14.5)     | 19 (10.4)    |         |           |
| No (n = 353)                                   | 189 (85.5)    | 164 (89.6)   |         |           |
| Dietician                                      | N = 222       | N = 185      | 1.00    | 1.0 (0.63–1.57) |
| Yes (n = 99)                                   | 54 (24.3)     | 45 (24.3)    |         |           |
| No (n = 308)                                   | 168 (75.7)    | 140 (75.7)   |         |           |
| Physiotherapist                                | N = 220       | N = 183      | 0.010   | 1.8 (1.1–3.0) |
| Yes (n = 97)                                   | 64 (29.1)     | 33 (18)      |         |           |
| No (n = 306)                                   | 156 (70.9)    | 150 (82)     |         |           |
| Exercise physiologist                          | N = 218       | N = 182      | 0.067   | 2.0 (0.93–4.3) |
| Yes (n = 33)                                   | 23 (10.6)     | 10 (5.5)     |         |           |
| No (n = 367)                                   | 195 (89.4)    | 172 (94.5)   |         |           |
| **Lifestyle**                                  |               |              |         |           |
| BMI group                                      | N = 239       | N = 193      | 0.519   | –         |
| Normal (193)                                   | 112 (46.9)    | 81 (42)      |         |           |
| Obesity (66)                                   | 36 (15.1)     | 30 (15.5)    |         |           |
| Overweight (125)                               | 66 (27.6)     | 59 (30.6)    |         |           |
| Underweight (13)                               | 9 (3.8)       | 4 (2.1)      |         |           |
| Missing (35)                                   | Median 24.48  | Median 25.1  |         |           |
| Median (IQR)                                   | (22.1–28.03)  | (22.5–28.3)  |         |           |
significant relationship with FACT-BMT and patients’ use of CAMs.

**Dietary modification**

Fifty-Nine (13.6%) HSCT survivors modified their diet in some way, including caloric supplementation (3; 0.7%), low calorie diet (6; 1.4%), gluten-free diet (6; 1.4%), lactose-free diet (3; 0.7%), probiotic usage (4; 0.9%), low carbohydrate diet (2; 0.5%), vegetarian or pescetarian diet (8; 1.8%), low cholesterol diet (4; 0.9%), and use of organic food (14; 3.2%). Women were more likely to make modifications to their diet post-HSCT than men, with 32 (17%) of women and 27 (11%) of men (Male: OR: 0.59 [0.34–1.03]). Nine HSCT survivors consulted a dietician (2%).

Diagnosis, comorbidities (diabetes mellitus, cardiovascular disease), bone disease, and posttransplant cancer diagnosis were not significantly associated with dietary modification. Those using dietary modification were significantly more likely to be further out from their transplant date (median 6.6 years compared to 5.0 years [P = 0.04]) and reported significantly higher FACT-BMT scores (Median 109, IQR 99–121), indicative of better quality of life.

**Herbal therapy**

Herbal therapies were uncommonly used by HSCT survivors, with the most common therapies including Ginseng (5; 1.1%) and Garlic (3; 0.7%). Women were more likely to use herbal therapies (Male: P = 0.056, OR: 0.58 [0.33–1.01]) as were patients living in an urban area (Rural: P = 0.051, odds 2.0 [0.98–4.14]). Although not significant, patients using herbal supplements had higher odds of having a pretransplant diagnosis of AML/ALL (OR: 1.42 [0.798–2.55]), cardiovascular risk factors (OR: 1.32 [0.73–2.39]), bone disease (OR: 1.7 [0.95–3.31]), and of seeing a psychiatrist (OR: 1.35 [0.49–3.70]). Those using herbal supplements had lower odds of being diabetic (OR: 0.83 [0.33–2.0]) or seeing a social worker (OR: 0.72 [0.21–1.92]) or a dietician (OR: 0.45 [0.19–1.04]). Patients were significantly less likely to take herbal supplements the more prescription medications they took (P = 0.004). There was no significant relationship between FACT-BMT and patient’s use of herbs.

**Vitamin therapy (including minerals and oils)**

Self-medication of vitamins (excluding Vitamin D and Calcium) was taken by 129 (29.3%) patients, including vitamin B (24; 5.4%), vitamin C (33; 7.5%), vitamin E (2; 0.5%), fish oil (28; 6.3%), magnesium (15; 3.4%), zinc (8; 1.8%), CoQ10 (3; 0.7%), and multivitamins (38; 8.6%). Calcium was taken by 211 (47.2%) patients and vitamin D by 250 (56.7%) patients (Table 4). Patients were more likely to take vitamin therapies if they had a university degree (OR: 1.36 [0.84–2.19], however, no other correlations were identified. Of the 239 patients taking vitamin supplements, the total number of supplements (supplement burden) varied, with most patients taking one (61; 51%) or two (32; 27%) supplements (Table 5).
Mind–body therapies (including spiritual healing)

Mind–body therapies were used by 74 (17.1%) patients, including meditation (45; 10.2%), hypnosis/breathing exercise (7; 1.6%), spiritual healing (9; 2.0%), yoga (8; 1.8%), and tai chi (5; 1.1%). Women were more likely to use mind–body therapies (22%) versus men (13%). Patients with university degrees were significantly more likely to use a spiritual and/or mental therapy (P = 0.008 OR: 2.20 [0.21–3.99]). Likewise, those who saw a Psychologist (P = 0.009, OR: 2.19 [1.21–3.99]), Psychiatrist (P = 0.015, OR: 2.62 [1.17–5.86]), Physiotherapist (P = 0.049, OR: 1.77[0.99–3.14]), Exercise physiologist (P = 0.022, OR: 2.48 [1.11–5.51]), or those who exercised more than three times per week (P = 0.042, OR: 0.48 [0.244–0.97]).

Manipulative and body-based therapies

Manipulative and body-based therapies were used by 112 (26%) patients, including acupuncture (28; 6.3%), chiropractic (28; 6.3%), massage (64; 14%), osteopathy (9; 2%), physiotherapy (8; 1.8%), and reflexology (6; 1.4%). There was a marginal difference in genders seen with 58 (31.2%) women and 54 (22%) men using physical therapies. Those patients with university degrees were significantly more likely to use a manipulative and body-based therapy (P = 0.001, OR: 2.24 [1.37–3.67]), whereas those with cGVHD also had a greater odds of use (OR: 1.38 [084 –2.26]).

Traditional Chinese/ayurvedic medicine, reiki, and homeopathy

Traditional Chinese/ayurvedic medicine was used by 15 (3.5%) patients, of which 10 (5.4%) were women and 5 (2.1%) were men. The patients were significantly less likely to take herbal traditional Chinese/ayurvedic medicine the more prescription medications they took (P = 0.023). Reiki (or “energy medicine”) was used by 13 (3%) patients, of which 10 (5.4%) were women and 3 (1.2%) were men. Homeopathy was used by 13 (3.1%) patients, of which 8 (4.4%) were women and 5 (2.1%) were men.

Discussion

In this survey of 583 allogeneic Australian HSCT survivors, over half (54.2%) used at least one CAM. The most common CAM therapies used were vitamin therapies (27.3%) and manipulative body-based therapies (26.0%), with survivors also using mind–body therapies (17.2%), dietary modification (13.6%), and herbal supplementation (13.5%). This usage is consistent with internationally reported CAM usage in cancer patients [6, 11]. The types of CAM therapies used by HSCT survivors in our study are similar to those used by cancer patients, with vitamins, manipulative body-based therapies, and herbal supplementation used more often than other CAMs.

Few participants (3.1%) reported using homeopathy compared to other studies in cancer patients, which report usage up to 10% [12]. This may reflect low rates of homeopathy usage in Australia compared to the United States, and/or the results of recent efforts by the Australian NHMRC (National Health and Medical Research Council) which released an advisory noting the absence of evidence for homeopathy and calling for restrictions on education and health insurance subsidies of homeopathy [13]. At the same time it is of some concern that only half of responders reported taking calcium (47.8%) and vitamin D supplements (56.7%), given that these have shown to be beneficial in this high-risk patient group [14].

As has been documented in other studies of CAM use, both in the general population and in cancer patients [6, 11, 12], we found a higher proportion of CAM usage by women (across all CAM subgroups), those with a university education and people living in a major city (which may be due to a lack of access to CAM in remote regions and smaller towns). We did not see any correlation between CAM usage and cGVHD or patient age. Although a cohort study using a questionnaire risks selection bias, with such a large response rate (76%) of our patient cohort of all contactable HSCT survivors over a 13-year period, we believe selection bias is minimal and this is an accurate proportion of CAM usage.

Given the number of HSCT survivors taking CAM therapies, it is important to be aware of the potential harms CAM therapies may have, including interactions with conventional allogeneic therapies, particularly immunosuppressants and antifungals, as well as risks of

Table 5. Vitamin supplementation burden.

| Number of vitamin supplements per patient excl calcium +Vit D | 1   | 2   | 3   | 4   | 5   | 6   | 7   |
|-------------------------------------------------------------|-----|-----|-----|-----|-----|-----|-----|
| 51% (61)                                                    | 27% (32) | 13% (16) | 5% (6) | 3% (4) | 0   | 0.8% (1) |
manipulative therapies in patients with underlying bone disease and potential harm of overuse of vitamins [15–17]. Other direct toxicity with CAM usage including diarrhea and vomiting are also a particular concern in transplant recipients as they may exacerbate concurrent gastrointestinal disease including cGVHD [16]. It is also possible that by increasing polypharmacy and the pill burden experienced by allogeneic HSCT survivors (a group already taking a large number of supportive care medications), CAM therapies may also increase the likelihood of nonadherence [18]. Alternatively, several randomized controlled studies, particularly mind and body interventions were found to have potential benefits in this patient group [9]. For example, Takatsuka et al. demonstrated a beneficial effect of fish oil on the incidence of graft-versus-host disease (GVHD) in patients after HSCT [19] and two studies have found a significant positive correlation between massage therapy and a decline in anxiety and depression level in patients after HSCT [20, 21]. Although our subgroup analysis did not replicate these results, with no significant differences in cGVHD or FACT-BMT scores, the design of the study was inadequate for this purpose; rather it has demonstrated that a large proportion of HSCT recipients are using these CAMs up to 10 years posttransplant.

It is crucial that CAM usage is routinely assessed as part of HSCT long-term follow-up (LTFU). While the decision to use a CAM always remains the right of the patient, it is essential that this decision to do so is informed. These results definitively demonstrate a large proportion of HSCT survivors are using one or more form of CAM therapy. Given the potential benefits demonstrated by small studies of specific CAM therapies in this patient group, as well as clearly documented therapies with no benefit or even toxicity, this result shows there is a large unmet need for additional studies to ascertain efficacy and safety of CAM therapies in this growing population.

Acknowledgments

This research was funded by the New South Wales Agency for Clinical Innovation (ACI) Blood and Marrow Transplant Network and supported by the Northern Blood Research Centre. These sponsors are public or nonprofit organizations that support health care redesign and medical science in general.

Conflict of Interest

None declared.

References

1. Pasquini, M. C. W. Z., 2013. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides. Available at: http://www.cibmtr.org. (accessed 24 July 2014).
2. Australasian Bone Marrow Transplant Recipient Registry. 2012. ABMTRR Annual Data Summary. In: Registry ABMTR, ed.
3. Mohty, B., and M. Mohty. 2011. Long-term complications and side effects after allogeneic hematopoietic stem cell transplantation: an update. Blood Cancer J. 1:e16.
4. Savani, B. N., M. L. Griffith, S. Jagasia, and S. J. Lee. 2011. How I treat late effects in adults after allogeneic stem cell transplantation. Blood 17:3002–3009.
5. Majhail, N. S., J. D. Rizzo, S. J. Lee, M. Aljurf, Y. Altsuta, C. Bonfim, et al. 2012. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Biol. Blood Marrow Transplant. 18:348–371.
6. Ernst, E., and B. R. Cassileth. 1998. The prevalence of complementary/alternative medicine in cancer: a systematic review. Cancer 15:777–782.
7. Horneber, M., G. Bueschel, G. Dennert, D. Less, E. Ritter, and M. Zwahlen. 2012. How many cancer patients use complementary and alternative medicine: a systematic review and metaanalysis. Integr. Cancer Ther. 11:187–203.
8. Anderson, J. G., and A. G. Taylor. 2012. Use of complementary therapies by individuals with or at risk for cardiovascular disease: results of the 2007 National Health Interview Survey. J. Cardiovasc. Nurs. 27:96–102.
9. Chakraborty, R., B. N. Savani, M. Litzow, M. Mohty, and S. Hashmi. 2015. A perspective on complementary/alternative medicine use among survivors of hematopoietic stem cell transplant: benefits and uncertainties. Cancer 15:2303–2313.
10. Australian Bureau of Statistics. 2013. Australian Demographic Statistics. (accessed November 12 2014).
11. Yates, J. S., K. M. Mustian, G. R. Morrow, L. J. Gillies, D. Padmanaban, J. N. Atkins, et al. 2005. Prevalence of complementary and alternative medicine use in cancer patients during treatment. Support. Care Cancer 13:806–811.
12. Richardson, M. A., T. Sanders, J. L. Palmer, A. Greisinger, and S. E. Singletary. 2000. Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J. Clin. Oncol. 18:2505–2514.
13. National Health and Medical Research Council. 2015. NHMRC statement on homeopathy and NHMRC information paper – evidence on the effectiveness of homeopathy for treating health conditions. National Health and Medical Research Council, Canberra.
14. Kananen, K., L. Volin, R. Tahtela, K. Laitinen, T. Ruutu, and M. J. Valimaki. 2002. Recovery of bone
mass and normalization of bone turnover in long-term survivors of allogeneic bone marrow transplantation. Bone Marrow Transplant. 29:33–39.

15. Leather, H. L. 2004. Drug interactions in the hematopoietic stem cell transplant (HSCT) recipient: what every transplanter needs to know. Bone Marrow Transplant. 33:137–152.

16. Markman, M. 2002. Safety issues in using complementary and alternative medicine. J. Clin. Oncol. 20(18 Suppl):39S–41S.

17. Werneke, U., J. Earl, C. Seydel, O. Horn, P. Crichton, and D. Fannon. 2004. Potential health risks of complementary alternative medicines in cancer patients. Br. J. Cancer 26:408–413.

18. Maggiore, R. J., W. Dale, C. P. Gross, T. Feng, W. P. Tew, S. G. Mohile, et al. 2014. Polypharmacy and potentially inappropriate medication use in older adults with cancer undergoing chemotherapy: effect on chemotherapy-related toxicity and hospitalization during treatment. J. Am. Geriatr. Soc. 62:1505–1512.

19. Takatsuka, H., Y. Takemoto, S. Yamada, T. Wakae, A. Mori, M. Okada, et al. 2002. Oral eicosapentaenoic acid for acute colonic graft-versus-host disease after bone marrow transplantation. Drugs Exp. Clin. Res. 28:121–125.

20. Phipps, S., C. Peasant, M. Barrera, M. A. Alderfer, Q. Huang, and K. Vannatta. 2012. Resilience in children undergoing stem cell transplantation: results of a complementary intervention trial. Pediatrics 129:e762–e770.

21. Rexilius, S. J., C. Mundt, M. Erickson Megel, and S. Agrawal. 2002. Therapeutic effects of massage therapy and handling touch on caregivers of patients undergoing autologous hematopoietic stem cell transplant. Oncol. Nurs. Forum 29:E35–E44.